Shankar Varadharajan and his Persons Acting in Concert (PACs) have increased their aggregate shareholding in Fischer Medical Ventures Limited to 62.50% of the total voting capital, following a recent acquisition of shares via warrant conversion. The transaction, completed on August 11, 2026, involved the preferential allotment of 23,00,000 equity shares to Mr. Varadharajan, raising his individual holding from 11.46% to 11.81%. This move consolidates the promoter group’s control over the Chennai-based medical device manufacturer, bringing their combined diluted voting power to 63.08%.

The disclosure was filed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, with both the BSE Limited and the National Stock Exchange of India Limited. The acquisition was executed through the conversion of warrants held by Mr. Varadharajan into equity shares. Consequently, his warrant holdings decreased from 1,10,00,000 to 87,00,000, while FMV Holdings Pte Ltd and Mr. Ravindran Govindan, who are part of the PAC group, saw no change in their respective equity or warrant positions during this specific transaction.

Shareholding Structure Post-Acquisition

The table below details the shareholding pattern of the acquirer and PACs before and after the acquisition:

In addition to equity shares, the group holds convertible instruments. Post-acquisition, Mr. Varadharajan retains 87,00,000 warrants, representing 1.25% of the diluted capital, while FMV Holdings Pte Ltd holds 2,30,00,000 warrants, accounting for 3.29% of the diluted capital. There are no encumbrances, pledges, or liens on any of the shares held by the acquirer or PACs.

Capital Structure Changes

The acquisition resulted in a marginal increase in the company’s authorized and issued equity capital. Prior to the allotment, Fischer Medical Ventures Limited’s equity share capital stood at ₹65,45,15,470, divided into 65,45,15,470 equity shares of Re. 1 each. Following the conversion of warrants into equity, the total equity share capital increased to ₹65,68,15,470, comprising 65,68,15,470 equity shares. The total diluted share/voting capital, assuming full conversion of outstanding convertible securities, is now ₹69,86,85,470.

What the Numbers Show

The consolidation of stake through warrant conversion rather than open market purchases or fresh cash infusion suggests a strategic tightening of control by the promoter group without immediate dilution for existing minority shareholders. With the promoter group now holding a two-thirds majority in voting rights (62.50%), they possess significant influence over corporate governance decisions, including board appointments and major policy changes. The reduction in outstanding warrants from Mr. Varadharajan’s portfolio indicates a step towards stabilizing the cap table, potentially reducing future dilution risks associated with these convertible instruments.

Time Medical International Ventures (India) Private Limited ("Time Medical India"), a wholly owned subsidiary of Fischer Medical Ventures Limited , has entered into a partnership with Parul Sevashram Hospital in Vadodara to install its DRIS-iMRI Medharanya Suite. Announced on July 31, 2026, the collaboration marks the deployment of an AI-enabled, next-generation portable intraoperative MRI system designed to enhance precision and safety in complex neurosurgical procedures through real-time visualization.

The partnership aligns with Parul Sevashram Hospital's vision of "Health for All" and its commitment to accessible, high-quality healthcare. As the teaching hospital of Parul Institute of Medical Sciences & Research, a constituent institute of Parul University, the facility serves a student community of over 43,000, including more than 2,500 international students from over 68 countries. Parul University is noted as one of India's largest multidisciplinary private universities and the youngest to receive NAAC A++ accreditation in its first assessment cycle.

Technology Overview

The DRIS-iMRI Medharanya Suite represents a new variant of MRI imaging technology developed by Time Medical India. The system integrates multiple advanced technologies into a single intelligent surgical ecosystem:

This integrated platform unifies diagnostic and surgical workflows, enabling faster decision-making and unparalleled visualization of complex neurological anatomy beyond conventional imaging methods.

Clinical and Academic Impact

Svetlana Rao, Director at Time Medical India, stated that the upcoming partnership will mark a landmark deployment of a next-generation intraoperative MRI Brain Suite in India. She noted that the collaboration is expected to enhance neurosurgical precision, improve clinical outcomes, and strengthen advanced neurocare capabilities at the hospital.

Beyond clinical applications, the installation is expected to strengthen the academic and clinical ecosystem at Parul University. The suite will provide medical students, residents, and faculty with hands-on exposure to next-generation neurosurgical imaging technology, supporting education across Medicine, Engineering, Pharmacy, Ayurveda, Homoeopathy, Management, Law, and Design faculties.

Development Collaboration

The DRIS-iMRI Medharanya platform is being jointly developed by Time Medical India in collaboration with Dr. Iype Cherian, a globally renowned neurosurgeon, educator, and innovator. Dr. Cherian completed his M.Ch (Neurosurgery) at CMC Vellore and advanced fellowship training in Skull Base and Vascular Neurosurgery at Nagoya, Japan. He is internationally recognized for pioneering neurosurgical techniques, including novel craniotomy approaches and the concept of Brain Cooling.

Time Medical India worked closely with surgeons to understand real-world requirements in building the solution. Headquartered in Chennai, Time Medical India specializes in the design and manufacture of high-performance, cost-effective MRI systems aimed at democratizing access to advanced diagnostic imaging across emerging and developed markets.